1. Wilkerson PM, Dedes KJ, Lopez-Garcia MA, Geyer FC, Reis-Filho JS (2011) The molecular evolution of breast cancer precursors and risk indicators. In: Kahán Z, Tot T (eds) Breast cancer, a heterogeneous disease entity. The very early stages. Springer Science+Business Media, Dordrecht, pp 89–117
2. Elston CW, Ellis IO, Pathological prognostic factors in breast cancer. I (1991) The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410
3. Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Borisch B, Bussolati G, Connolly CE, Cserni G, Decker T, Dervan P, Drijkoningen M, Ellis IO, Elston CW, Eusebi V, Faverly D, Heikkila P, Holland R, Kerner H, Kulka J, Jacquemier J, Lacerda M, Martinez-Penuela J, De Miguel C, Nordgren H, Peterse JL, Rank F, Regitnig P, Reiner A, Sapino A, Sigal-Zafrani B, Tanous AM, Thorstenson S, Zozaya E, Wells CA, EC Working Group on Breast Screening Pathology (2006) Quality assurance guidelines for pathology. In: Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. European Comission, Luxemburg, pp 219–311
4. Ellis IO, Carder P, Hales S, Lee AHS, Pinder SE, Rakha E, Al-Sam S, Deb R, Hanby A, Liebmann R, Provenzano E, Rowlands D, Wells CA, Anderson N, Girling A, Ibrahim M, Mallon E, Quinn C (2016) Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. The Royal College of Pathologists. https://www.rcpath.org/uploads/assets/uploaded/c5a73c7a-50a4-4077-8815c49abbcbc1f1.pdf. Accessed 13 May 2019
5. Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E (2009) Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med 133:15–25